Previous 10 | Next 10 |
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference ...
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the “Board”) and Thomas F. Isett, the Company ...
– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in ~50% annualized cost savings ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It has been a rough year for investors, with the S&P 500 index posting incredible losses not seen in some time. As stocks continue to hover in this fragile market, investors must consider which assets are most valuabl...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although contrarianism captured headlines through the first two years of the coronavirus pandemic, it’s now time for investors to consider the topic of short-squeeze stocks to sell before traders cash out. Fundamen...
Cantor Fitzgerald has downgraded the contract manufacturer iBio, Inc. ( NYSE: IBIO ) to Neutral from Overweight, citing a lack of near-term catalysts after the company recently decided to end its COVID-19 vaccine development and instead focus on immuno-oncology. The an...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Fed’s key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result,...
Cantor Fitzgerald defended iBio ( NYSE: IBIO ) after the biotech announced its intention not to seek FDA clearance next year to study its multi-variant COVID-19 vaccine candidate IBIO-202 triggering a sharp decline in its shares in the morning hours Wednesday. ...
iBio, Inc. (IBIO) Q4 2022 Earnings Conference Call September 27, 2022, 04:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Rob Lutz - Chief Financial and Business Officer Martin Brenner - Chief...
iBio press release ( NYSE: IBIO ): FY Revenue of $2.4M (+1.3% Y/Y) misses by $0.15M . Net loss was $50.3 million, an increased loss of $27.1 million compared to 2021 due to increased R&D and administrative expenses incurred. iBio held cash, cash equivalents and...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...